Ultragenyx Pharmaceutical, Inc. (RARE)
23.50
-0.38
(-1.59%)
USD |
NASDAQ |
Feb 12, 16:00
22.65
-0.85
(-3.62%)
After-Hours: 07:47
Ultragenyx Pharmaceutical Cash from Investing (Quarterly) : 117.18M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 14.64M |
| Johnson & Johnson | -4.485B |
| CorMedix, Inc. | -291.32M |
| Insmed, Inc. | -762.23M |
| Apellis Pharmaceuticals, Inc. | -0.148M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -91.42M |
| Cash from Financing (Quarterly) | 0.002M |
| Free Cash Flow | -466.39M |
| Free Cash Flow Per Share (Quarterly) | -0.9291 |
| Free Cash Flow to Equity (Quarterly) | -72.91M |
| Free Cash Flow to Firm (Quarterly) | -78.48M |
| Free Cash Flow Yield | -20.34% |